show episodes
 
Artwork

1
The Top Line

Fierce Life Sciences

Unsubscribe
Unsubscribe
Weekly
 
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
  continue reading
 
Artwork

1
The Fiends

The Fiends Podcast Network

Unsubscribe
Unsubscribe
Monthly+
 
West Coast Homers from San Jose State University Caleb Hodgson, Hunter Gore, and Brett Orloff offer a correct blend of fan perspective, film analysis, and degenerate hot takes recapping each Las Vegas Raider, San Fransico 49er, and New England Patriots games from the past weekend of football. They will also dive into some of the week's biggest headlines from around the sports world. New Episodes every Wednesday.
  continue reading
 
Artwork

1
House of The Fiends

The Fiends Podcast Network

Unsubscribe
Unsubscribe
Daily+
 
Lifelong Best Friends and readers of the Book Fire and Blood (the prequel to The Game of Thrones Book/TV series) Caleb Hodgson and Hunter Gore provide episode-by-episode recaps of the hit HBO Show House of the Dragon. Without being a spoiler podcast, The Fiends provides you with an in-depth recap immediately following the newest episode release; highlighting the changes from the book to the show, their off-the-cuff predictions, and overall opinions of the episode. New Episodes are released e ...
  continue reading
 
Loading …
show series
 
The Fiends are back from a two-week hiatus with a special in-person recording session for the first time in show history. Brett gives us insight into the environment he experienced in Corvallis last weekend, where the Spartans took down Oregon State in one of the biggest wins in program history. Hunter is not worried about the Niners as they win in…
  continue reading
 
 Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated i…
  continue reading
 
Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate high risks and harsh realities. In this week's episode of "The Top Line," Fierce editors Gabrielle Masson and Andrea Park take a closer look at this year’s biotech graveyard, which tracks biotechs that have shuttered or are in the …
  continue reading
 
As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy. While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly. In this week's episode of "T…
  continue reading
 
Caleb is so tired after pilates, it’s got him feeling like Anthony Richardson. The Jets are the worst team in America. Brett breaks down the Pat's defensive performance and the impact of Drake Maye's Injury. Caleb takes a mental health day, as the Raiders fall to the rival Chiefs. The boys discuss their half-baked MVP, Super Bowl, and bold predicti…
  continue reading
 
Discover how Turbine Simulated Cell Technologies is transforming drug development by addressing biases in training data. Guests Bence Szalai, MD, PhD, and Istvan Taisz, MD, PhD, share insights on the challenges of biased AI models in biology and introduce their groundbreaking framework, EFFECT (Evaluation Framework for Predicting Efficacy of Cancer…
  continue reading
 
EY recently published their 18th annual Pulse of the MedTech Industry report, highlighting how—despite steadily rising profits year-over-year—devicemakers large and small are still being squeezed by the cost of doing business and waning investor enthusiasm. During AdvaMed’s MedTech Conference this month in Toronto, John Babbitt, partner on the life…
  continue reading
 
The boys start the pod by sharing sports trauma, and reminding Brett how great his sports life has been. Hunter is not worried about the Niners, but Kyle and Purdy are under fire after a pathetic performance against the Chiefs. It's the Bugatti Drake Maye Daye in London!!! The boys discuss Mayo’s postgame comments after a tough loss. Bill throwing …
  continue reading
 
At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future. Fierce Biotech’s Gabrielle Masson sat down with Liang Schwei…
  continue reading
 
The Fiends get into the news of the day with Caleb giving his take on Tae Adams to the Jets and Brett's analysis on Amari Cooper's fit in the Bills offense. Raiders are cooked, but the introduction of Brady into the ownership group may bring hope to Caleb and Raiders fans everywhere. If we can get him out of the announcer's booth and in charge of t…
  continue reading
 
In this episode, we dive into the world of gene therapy logistics with Cryoport Systems' innovative Elite Ultra Cold shipping system. Mike Dybicz and Khoa Tran are in the hotseat to discuss how their solution addresses critical challenges in transporting temperature-sensitive gene therapies. The pair explain how Cryoport Elite offers extended hold …
  continue reading
 
The neuroscience sector has seen a surge in investment over the past year, leading to breakthroughs and high-stakes deals, especially in the closing months of 2023. This momentum shows no signs of slowing, as companies continue to push boundaries in neuroscience and psychiatric disease research. At this year's Fierce Biotech Summit on Oct. 1, pharm…
  continue reading
 
Caleb and Hunter deep dive into everything that happened in Season 1 of House of the Dragon. They tackle the Council of 101 AC, the character changes mid-season, the relationship between Alicent and Rhaenrya, the main differences between the show and the book, set pieces, sound design, costume design, favorite moments of season 1, and predictions f…
  continue reading
 
The Fiends jump straight into the news of the day with a discussion about Robert Saleh getting fired by the Jets (0:16 - 14:38). Brett’s expectations as Drake Maye gets the start in week six against the Texans (14:39- 29:17). Up next for the boys is a deep dive into the 49er's struggles on both ends and what Hunter's expectations for the rest of th…
  continue reading
 
Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculated on what the legislation could mean for the life sciences industry. In this week's episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner sits down with Arnold & Porter’s Life Sciences practice chair Dan Kracov to…
  continue reading
 
Caleb hates “sources”, as the boys explore the Tuesday drama linked to the supposed Devante Adams trade request (0.00-11:50). Raiders take down Massage Watson, With Caleb and Brett breaking down the scrappy Raiders defense, along with the rising star Brock Bowers. (11:57-27:30). We have a Pod faceoff on our hands!!! Brett tells the hard truth about…
  continue reading
 
At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questi…
  continue reading
 
Segments "Film Talk" with Brett Pats Jets (TNF ) Positives/Worries Maye garbage time reps? Outlook for the rest of the season @ 49ers next week Niners Rams (Injury Bowl) QB Show Positives/worries Outlook for 49ers rest of season Mcvay/Shanny Raiders Panthers Fluke or panic time in LV? APs comments Positives/worries Outlook for Raiders rest of seaso…
  continue reading
 
Show Script Raidas upset the Ravens Mad Max = Game Wrecker Who’s laughing at Bowers's pick now? Road to Success looking ahead? Gardner's stats look good lol Niners vs Vikings: The Flores Game Injuries haunting? Did Flores outcoach Shanny?- Fred Warner becoming an all-time great ILB What is it about Kyle's drop-back game that has experts questioning…
  continue reading
 
In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East, which took place in Philadelphia last week. The event brought together marketing experts from across the life sciences industry. Fierce Pharma Marketing's Andrea Park and Ben Adams talk about major trends from the event that came up …
  continue reading
 
In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. We share the stories of a select few 2024 Fierce 50 honorees and interesting highlights from this year's special report. To learn more about the topics in this episode: Fierce 50 of 2024 Innovation Honorees Health Equity Honorees Social Impact Honorees …
  continue reading
 
In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. Fierce Pharma’s Zoey Becker chats with Stefan Merlo, vice president of commercial operations, North America at CSL Seqirus. He discusses the company's differentiated flu vaccine portfolio and how its manufacturing process has evolved …
  continue reading
 
Caleb's Intro - Farewell to the Pac12 intro CFB Week 1 Recap: - Conference realignment - NIL World - Expanded 12-team playoff - Brian Kelly Hate session - Has Colorado improved? - Hunter and Sanders as NFL Prospects? SJSU vs Sac State - Coach Ken wins in debut - Is Nick Nash a "Biletnikoff" threat? NFL? - Predictions for a new era at SJ Oregon Chec…
  continue reading
 
In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond. Fierce Pharma’s Zoey Becker chats with Gregg Sylvester, M.D., Chief Health Officer at CSL Seqirus, to get insight on what we might expect to see from this upcoming flu season. He also explains efforts to incre…
  continue reading
 
Intro: Welcome Brett Orloff to the Fiends Explain the new show format NFL Football Preview/Half-Baked Predictions Raiders Preview with Caleb 49er Preview with Hunter Pats Preview with Brett Super Bowl predictions MVP predictions 1-2 half-baked takes per person…… (revisit after season)By The Fiends Podcast Network
  continue reading
 
Biotherapeutics are transforming healthcare for over 350 million patients globally, tackling everything from cancer and diabetes to rare diseases. Human embryonic kidney (HEK) 293 cells play a key role in the manufacturing of many of these life-changing products. However, they are not without their challenges. In this episode of The Top Line, spons…
  continue reading
 
For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of agencies. This stipulation, called the Chevron deference, gave agencies room to advance their regulatory priorities. The Supreme Court overturned the doctrine in June, bringing significant implications …
  continue reading
 
The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gilead Sciences, AstraZeneca and Merck. Fierce Pharma’s Angus Liu recently took a deep dive into the three TROP2 front-runners. In a feature article, he examined the strengths and potential challenges facing each candidate, as well as the considerations behind th…
  continue reading
 
In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. Fierce Biotech's Annalee Armstrong and Gabrielle Masson take you behind the scenes to explore the meticulous selection process and share interesting highlights from this year’s honorees. To learn more about the topics in this episode: Intro…
  continue reading
 
This week on “The Top Line,” we discuss two studies in HIV research that were presented at the 25th International AIDS Conference in Germany. One of them is the report of a 7th person who has likely been cured of HIV. And there’s something unique about this case that has sparked excitement among scientists. The other one is the report of a long-act…
  continue reading
 
In this week’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014. A decade later, she revisits these trailblazers to see how they’ve navigated the biotech landscape. To learn more about the topics in this episode: Fierce Biotech's Fierc…
  continue reading
 
Back in February, Novo Holdings laid out a $16.5 billion deal to snap up contract manufacturing giant Catalent. In this week's episode of "The Top Line," we dive into the current state and implications of the proposed buyout. Fierce Pharma’s Fraiser Kansteiner is joined by former FTC policy director David Balto. They discuss the likelihood of the d…
  continue reading
 
In this episode of The Top Line, sponsored by the Parenteral Drug Association (PDA), we explore the upcoming PDA/FDA Joint Regulatory Conference, happening September 9-11 in Washington, D.C. Our guest, Janeen Skutnik-Wilkinson, Director of Global Quality Regulatory Surveillance and External Engagement for Moderna and Co-Chair of the 33rd annual eve…
  continue reading
 
Pharmaceutical CEOs often earn pay packages worth tens of millions of dollars for leading the top drugmaking companies in the industry. Every year, some new faces enter the rankings while others leave. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma…
  continue reading
 
At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting. In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years. From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s…
  continue reading
 
In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing. "Friend-shoring" involves conducting manufacturing processes in countries considered friendly or allied. Sheng discusses the criteria for deeming a count…
  continue reading
 
Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech’s Gabrielle Masson and Fierce Pharma’s Angus Liu …
  continue reading
 
The Fierce Pharma Marketing team publishes a special report each year on the top pharmaceutical drug ad spenders. This year’s report, which includes numbers for 2023, was published on Monday. AbbVie was the standout in this edition, having spent heavily on ads for Skyrizi and Rinvoq. Overall spending on the top 10 ads also experienced a sizable inc…
  continue reading
 
The Fierce Biotech team published a four-part series this week exploring cell therapy, a modality that has faced clinical challenges, manufacturing constraints and multiple practice-changing events. In today’s episode, Fierce’s Annalee Armstrong and Gabrielle Masson discuss the series of special reports and key insights from their interviews with m…
  continue reading
 
This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner is joined by Bruce Levine, Ph.D., who is the co-inventor of Kymriah and the Barbara and Edward Netter Professor in Cancer Gene Therapy at the …
  continue reading
 
In the fast-paced field of life sciences, digital pathology is poised to be a game-changer. In this episode, we sit down with Grace Lee and Douglas Clark of Agilent Technologies to explore the opportunities and challenges associated with companion diagnostics (CDx). Clark kicks off, shedding light on the current levels of digital pathology adoption…
  continue reading
 
What is the transformative potential of digital health technologies in advancing health equity? Rabin Martin, a global health consulting firm, explores those possibilities in this engaging episode. The conversation highlights the excitement surrounding digital tools and advanced analytics in achieving deeper insights, consistent care delivery, work…
  continue reading
 
This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle…
  continue reading
 
This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner sits down with Ori Biotech CEO Jason Foster and the Cell Therapy Manufacturing Center's CEO, Jason Bock. They delve into the current state of cell and gene therapy …
  continue reading
 
This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the n…
  continue reading
 
Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023. This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight k…
  continue reading
 
This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce. This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our bian…
  continue reading
 
Jeff Beck of BioCare is in the hotseat for this edition of The Top Line. Beck is the Chief Development Officer at the company, which stands tall as a pioneer in specialty product distribution with over 40 years of experience dating back to hemophilia therapies. During the conversation, Beck provides an inside look at the rapidly evolving specialty …
  continue reading
 
This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024. Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the f…
  continue reading
 
Loading …

Quick Reference Guide